Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia

Zahinoor Ismail, Alette M. Wessels, Hiroyuki Uchida, Wenzie Ng, David C. Mamo, Tarek K. Rajji, Bruce G. Pollock, Benoit H. Mulsant, Robert Bies

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

BACKGROUND: Although clozapine is primarily used in a younger to mid-life population of patients with psychosis, there are limited data on the clinical pharmacology of clozapine later in life. The objective of this study was to assess the magnitude and variability of plasma concentrations of clozapine and norclozapine across the lifespan in a real-world clinical setting. DESIGN: A population pharmacokinetic study using nonlinear mixed effect modeling (NONMEM). Age, sex, height, weight, and dosage formulation were covariates. SETTING: Inpatients and outpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007. PARTICIPANTS: Patients ranging in ages from 11 to 79 with schizophrenia spectrum disorders and prescribed clozapine (Clozaril). MEASUREMENTS: A total of 1142 plasma clozapine and norclozapine concentrations (2,284 concentration measurements) from 391 patients with schizophrenia spectrum disorder. RESULTS: A one-compartment model with first-order absorption and elimination best described the data. The population predicted clearance of clozapine for females was 27.1 L/h (SE 11.1%) and 36.7 L/h (SE 9.7%) for males. For norclozapine, clearance in females was 48.6 L/h (SE 10.8%) and 63.1 L/h (SE 9.3%) in males. The only covariates with a significant effect on clearance were age and sex: clearance for both parent and metabolite decreased exponentially with age at least 39 years. CONCLUSIONS: Decreased clearance of clozapine and norclozapine with age results in increased blood concentrations and, hence, the potential for adverse drug reactions. These findings have particular clinical relevance for the dosing and safety monitoring of clozapine in older adults, highlighting a need for increased vigilance.

Original languageEnglish
Pages (from-to)53-60
Number of pages8
JournalAmerican Journal of Geriatric Psychiatry
Volume20
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Clozapine
norclozapine
Inpatients
Schizophrenia
Outpatients
Population
Clinical Pharmacology
Drug-Related Side Effects and Adverse Reactions
Psychotic Disorders
Mental Health
Pharmacokinetics
Safety
Weights and Measures

Keywords

  • Age
  • clearance
  • clozapine
  • nonlinear mixed effect model
  • pharmacokinetics
  • plasma concentration
  • population pharmacokinetics
  • sex

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. / Ismail, Zahinoor; Wessels, Alette M.; Uchida, Hiroyuki; Ng, Wenzie; Mamo, David C.; Rajji, Tarek K.; Pollock, Bruce G.; Mulsant, Benoit H.; Bies, Robert.

In: American Journal of Geriatric Psychiatry, Vol. 20, No. 1, 01.2012, p. 53-60.

Research output: Contribution to journalArticle

Ismail, Zahinoor ; Wessels, Alette M. ; Uchida, Hiroyuki ; Ng, Wenzie ; Mamo, David C. ; Rajji, Tarek K. ; Pollock, Bruce G. ; Mulsant, Benoit H. ; Bies, Robert. / Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. In: American Journal of Geriatric Psychiatry. 2012 ; Vol. 20, No. 1. pp. 53-60.
@article{c41fcea504124ce1a9fcca2db03b89dd,
title = "Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia",
abstract = "BACKGROUND: Although clozapine is primarily used in a younger to mid-life population of patients with psychosis, there are limited data on the clinical pharmacology of clozapine later in life. The objective of this study was to assess the magnitude and variability of plasma concentrations of clozapine and norclozapine across the lifespan in a real-world clinical setting. DESIGN: A population pharmacokinetic study using nonlinear mixed effect modeling (NONMEM). Age, sex, height, weight, and dosage formulation were covariates. SETTING: Inpatients and outpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007. PARTICIPANTS: Patients ranging in ages from 11 to 79 with schizophrenia spectrum disorders and prescribed clozapine (Clozaril). MEASUREMENTS: A total of 1142 plasma clozapine and norclozapine concentrations (2,284 concentration measurements) from 391 patients with schizophrenia spectrum disorder. RESULTS: A one-compartment model with first-order absorption and elimination best described the data. The population predicted clearance of clozapine for females was 27.1 L/h (SE 11.1{\%}) and 36.7 L/h (SE 9.7{\%}) for males. For norclozapine, clearance in females was 48.6 L/h (SE 10.8{\%}) and 63.1 L/h (SE 9.3{\%}) in males. The only covariates with a significant effect on clearance were age and sex: clearance for both parent and metabolite decreased exponentially with age at least 39 years. CONCLUSIONS: Decreased clearance of clozapine and norclozapine with age results in increased blood concentrations and, hence, the potential for adverse drug reactions. These findings have particular clinical relevance for the dosing and safety monitoring of clozapine in older adults, highlighting a need for increased vigilance.",
keywords = "Age, clearance, clozapine, nonlinear mixed effect model, pharmacokinetics, plasma concentration, population pharmacokinetics, sex",
author = "Zahinoor Ismail and Wessels, {Alette M.} and Hiroyuki Uchida and Wenzie Ng and Mamo, {David C.} and Rajji, {Tarek K.} and Pollock, {Bruce G.} and Mulsant, {Benoit H.} and Robert Bies",
year = "2012",
month = "1",
doi = "10.1097/JGP.0b013e3182118318",
language = "English",
volume = "20",
pages = "53--60",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia

AU - Ismail, Zahinoor

AU - Wessels, Alette M.

AU - Uchida, Hiroyuki

AU - Ng, Wenzie

AU - Mamo, David C.

AU - Rajji, Tarek K.

AU - Pollock, Bruce G.

AU - Mulsant, Benoit H.

AU - Bies, Robert

PY - 2012/1

Y1 - 2012/1

N2 - BACKGROUND: Although clozapine is primarily used in a younger to mid-life population of patients with psychosis, there are limited data on the clinical pharmacology of clozapine later in life. The objective of this study was to assess the magnitude and variability of plasma concentrations of clozapine and norclozapine across the lifespan in a real-world clinical setting. DESIGN: A population pharmacokinetic study using nonlinear mixed effect modeling (NONMEM). Age, sex, height, weight, and dosage formulation were covariates. SETTING: Inpatients and outpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007. PARTICIPANTS: Patients ranging in ages from 11 to 79 with schizophrenia spectrum disorders and prescribed clozapine (Clozaril). MEASUREMENTS: A total of 1142 plasma clozapine and norclozapine concentrations (2,284 concentration measurements) from 391 patients with schizophrenia spectrum disorder. RESULTS: A one-compartment model with first-order absorption and elimination best described the data. The population predicted clearance of clozapine for females was 27.1 L/h (SE 11.1%) and 36.7 L/h (SE 9.7%) for males. For norclozapine, clearance in females was 48.6 L/h (SE 10.8%) and 63.1 L/h (SE 9.3%) in males. The only covariates with a significant effect on clearance were age and sex: clearance for both parent and metabolite decreased exponentially with age at least 39 years. CONCLUSIONS: Decreased clearance of clozapine and norclozapine with age results in increased blood concentrations and, hence, the potential for adverse drug reactions. These findings have particular clinical relevance for the dosing and safety monitoring of clozapine in older adults, highlighting a need for increased vigilance.

AB - BACKGROUND: Although clozapine is primarily used in a younger to mid-life population of patients with psychosis, there are limited data on the clinical pharmacology of clozapine later in life. The objective of this study was to assess the magnitude and variability of plasma concentrations of clozapine and norclozapine across the lifespan in a real-world clinical setting. DESIGN: A population pharmacokinetic study using nonlinear mixed effect modeling (NONMEM). Age, sex, height, weight, and dosage formulation were covariates. SETTING: Inpatients and outpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007. PARTICIPANTS: Patients ranging in ages from 11 to 79 with schizophrenia spectrum disorders and prescribed clozapine (Clozaril). MEASUREMENTS: A total of 1142 plasma clozapine and norclozapine concentrations (2,284 concentration measurements) from 391 patients with schizophrenia spectrum disorder. RESULTS: A one-compartment model with first-order absorption and elimination best described the data. The population predicted clearance of clozapine for females was 27.1 L/h (SE 11.1%) and 36.7 L/h (SE 9.7%) for males. For norclozapine, clearance in females was 48.6 L/h (SE 10.8%) and 63.1 L/h (SE 9.3%) in males. The only covariates with a significant effect on clearance were age and sex: clearance for both parent and metabolite decreased exponentially with age at least 39 years. CONCLUSIONS: Decreased clearance of clozapine and norclozapine with age results in increased blood concentrations and, hence, the potential for adverse drug reactions. These findings have particular clinical relevance for the dosing and safety monitoring of clozapine in older adults, highlighting a need for increased vigilance.

KW - Age

KW - clearance

KW - clozapine

KW - nonlinear mixed effect model

KW - pharmacokinetics

KW - plasma concentration

KW - population pharmacokinetics

KW - sex

UR - http://www.scopus.com/inward/record.url?scp=84155165132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155165132&partnerID=8YFLogxK

U2 - 10.1097/JGP.0b013e3182118318

DO - 10.1097/JGP.0b013e3182118318

M3 - Article

VL - 20

SP - 53

EP - 60

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 1

ER -